Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy

Semin Oncol. 1998 Jun;25(3 Suppl 8):28-32.

Abstract

The effective treatment of non-small cell lung cancer requires both locoregional and systemic therapy. Outcome in intermediate-stage malignancies of the chest may be improved by combining chemotherapy and radiotherapy. Several combined-modality trials involving the platinum compounds, vinorelbine, gemcitabine, and the taxanes have been recently conducted. In one such phase I dose-escalation study of 29 patients with non-small cell lung cancer or esophageal cancer, the concurrent administration of docetaxel and radiotherapy at a dose of 2 Gy/d for 6 weeks was shown to be feasible. Objective tumor responses were observed, and further studies of docetaxel in combination with radiotherapy are indicated.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / radiotherapy*
  • Combined Modality Therapy
  • Docetaxel
  • Esophageal Neoplasms / drug therapy*
  • Esophageal Neoplasms / radiotherapy*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / radiotherapy*
  • Male
  • Middle Aged
  • Paclitaxel / analogs & derivatives*
  • Paclitaxel / therapeutic use
  • Taxoids*

Substances

  • Antineoplastic Agents, Phytogenic
  • Taxoids
  • Docetaxel
  • Paclitaxel